Trial · NCT02385279

Study Comparing the MiStent SES Versus the XIENCE EES Stent

NCT02385279, Not applicable, Completed, ECRI bv; results first posted 2023-05-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study Comparing the MiStent SES Versus the XIENCE EES Stent. Trials, record NCT02385279. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02385279

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study Comparing the MiStent SES Versus the XIENCE EES Stent
NCT number: NCT02385279
Status: Completed
Phases: Not applicable
Enrollment: 1,398 participants, actual
Lead sponsor: ECRI bv
Conditions: Coronary Stenosis
Interventions: MiStent, XIENCE EES
First posted: 2015-03-11
Last updated: 2023-05-08
Results first posted: 2023-05-08

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)	12 months postprocedure	DOCE is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and clinically-indicated target lesion revascularization.
Secondary	POCE	At 12 months	POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization
Secondary	MACE	At 12 months	MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR)
Secondary	Target Vessel Failure (TVF)	At 12 months	Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically indicated TVR
Secondary	All-cause Death	At 12 months	All-cause death
Secondary	Myocardial Infarction	At 12 months	Any Myocardial infarction
Secondary	Any Revascularization	At 12 months	Any revascularization
Secondary	Stent Thrombosis	At 12 months	Definite or probably stent thrombosis according to ARC

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)	12 months postprocedure	Intention-to-treat	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	POCE	At 12 months	ITT	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	MACE	At 12 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Target Vessel Failure (TVF)	At 12 months	ITT	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	All-cause Death	At 12 months	ITT	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Myocardial Infarction	At 12 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Any Revascularization	At 12 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Stent Thrombosis	At 12 months		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)	MiStent®	40	Participants
Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)	XIENCE EES	45	Participants
POCE	MiStent®	93	Participants
POCE	XIENCE EES	101	Participants
MACE	MiStent®	65	Participants
MACE	XIENCE EES	65	Participants
Target Vessel Failure (TVF)	MiStent®	45	Participants
Target Vessel Failure (TVF)	XIENCE EES	53	Participants
All-cause Death	MiStent®	25	Participants
All-cause Death	XIENCE EES	18	Participants

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	MiStent®	703
Overall Study	STARTED	XIENCE EES	695
Overall Study	COMPLETED	MiStent®	676
Overall Study	COMPLETED	XIENCE EES	677
Overall Study	NOT COMPLETED	MiStent®	27
Overall Study	NOT COMPLETED	XIENCE EES	18

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Non Serious AE	General disorders	MiStent®	76	703
other	Non Serious AE	General disorders	XIENCE EES	71	695
serious	Myocardial infarction	Cardiac disorders	MiStent®	17	703
serious	Myocardial infarction	Cardiac disorders	XIENCE EES	15	695
serious	Definite stent thrombosis	Cardiac disorders	MiStent®	3	703
serious	Definite stent thrombosis	Cardiac disorders	XIENCE EES	5	695
serious	Other	General disorders	MiStent®	414	703
serious	Other	General disorders	XIENCE EES	406	695

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	MiStent®	85	703
Total, all-cause mortality	XIENCE EES	78	695
Total, other adverse events	MiStent®	76	703
Total, other adverse events	XIENCE EES	71	695
Total, serious adverse events	MiStent®	434	703
Total, serious adverse events	XIENCE EES	426	695

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29203070	BACKGROUND	PubMed
32466676	DERIVED	PubMed
32888011	DERIVED	PubMed
34666500	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons10

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
MiStent® vs XIENCE EES: All-cause Death	Trial comparisons
MiStent® vs XIENCE EES: Myocardial Infarction	Trial comparisons
MiStent® vs XIENCE EES: POCE	Trial comparisons
MiStent® vs XIENCE EES: Stent Thrombosis	Trial comparisons
MiStent® vs XIENCE EES: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)	Trial comparisons
MiStent® vs XIENCE EES: Any Revascularization	Trial comparisons
MiStent® vs XIENCE EES: Target Vessel Failure (TVF)	Trial comparisons
MiStent® vs XIENCE EES: deaths from any cause	Trial comparisons
MiStent® vs XIENCE EES: MACE	Trial comparisons
MiStent® vs XIENCE EES: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02385279

GET https://conductscience.org/api/trials/v1/NCT02385279/registered

API reference For AI assistants